Hikaru Hori, MD, PhD

Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan

JCP
BI 1358894 in Patients With Inadequate Antidepressant Response
Original Research

September 3, 2025

No differences were observed between BI 1358894 treatment groups and placebo for primary and secondary endpoints. BI 1358894 was well tolerated with no increase in self-harm or suicidality.
, , , et al
JCP
Celecoxib Augmentation of Vortioxetine for Cognition in MDD
Original Research

October 4, 2023

Anti-inflammatory augmentation of vortioxetine did not provide additional benefit in reducing cognitive symptoms of MDD.
, , , et al
JCP
Original Research

November 20, 2018

In your patients with MDD, cognitive deficits may have a greater impact than you realize. This study used the THINC-it assessment to determine the extent to which impaired cognition...
, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe